Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 146-152

  Zhang, Yanling ^a,b,c   Yan, Hao ^a,b   Tian, Lin ^a,b   Wang, Fang ^a,b   Lu, Tianlan ^a,b   Wang, Lifang ^a,b   Yan, Jun ^a,b   Liu, Qi ^a,b   Kang, Lan ^a,b   Ruan, Yanyan ^a,b   Zhang, Dai ^a,b   Yue, Weihua ^a,b  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c Beijing Aerospace General Hospital   (China)

Author keywords

Association study; Episodic memory (EM); Gray matter density (GMD); Methylenetetrahydrofolate reductase (MTHFR); Schizophrenia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; THYMINE;

ADULT; ALLELE; ANALYTIC METHOD; ARTICLE; BRAIN FUNCTION; BRAIN SIZE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; EPISODIC MEMORY; FEMALE; FRONTAL CORTEX; FUNCTIONAL ASSESSMENT; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GRAY MATTER; HUMAN; INFERIOR FRONTAL GYRUS; INSULA; MAJOR CLINICAL STUDY; MALE; MIDDLE TEMPORAL GYRUS; MTHFR GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARAHIPPOCAMPAL GYRUS; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; RIGHT TEMPORAL GYRUS; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; TEMPORAL CORTEX; TEMPORAL GYRUS;

ADULT; ALLELES; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MEMORY, EPISODIC; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84873818934     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.061     Document Type: Article

References (64)

1. Cannon T.D., Kaprio J., Lonnqvist J., Huttunen M., Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort: a population-based modeling study. Archives of General Psychiatry 1998, 55:67-74.
2. Cardno A.G., Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics 2000, 97:12-17.
3. Kendler K.S., Gardner C.O. The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies. Psychological Medicine 1997, 27:411-419.
4. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry 2003, 60:1187-1192.
5. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics 2008, 40:827-834.
6. Leclerc C., Sibani S., Rozen R. Molecular biology of methylenetetra-hydrofolate reductase (MTHFR) and overview of mutations/polymorphisms. MTHFR polymorphisms and disease 2005, 1-20. Landes Bioscience, Texas, USA. 1st ed. P.M. Ueland, R. Rozen (Eds.).
7. Gilbody S., Lewis S., Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. American Journal of Epidemiology 2007, 165:1-13.
8. Arinami T., Yamada N., Yamakawa-Kobayashi K., Hamaguchi H., Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. American Journal of Medical Genetics 1997, 74:526-528.
9. Feng L.G., Song Z.W., Xin F., Hu J. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: a Chinese Han population-based case-control study. Psychiatry Research 2009, 168:205-208.
10. Joober R., Benkelfat C., Lal S., Bloom D., Labelle A., Lalonde P., et al. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Molecular Psychiatry 2000, 5:323-326.
11. Kempisty B., Mostowska A., Gorska I., Łuczak M., Czerski P., Szczepankiewicz A., et al. Association of 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene with bipolar disorder and schizophrenia. Neuroscience Letters 2006, 400:267-271.
12. Muntjewerff J.W., Hoogendoorn M.L., Kahn R.S., Sinke R.J., Den Heijer M., Kluijtmans L.A., et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 135B:69-72.
13. Sazci A., Ergul E., Guzelhan Y., Kaya G., Kara I. Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Brain Research. Molecular Brain Research 2003, 117:104-107.
14. Sazci A., Ergul E., Kucukali I., Kara I., Kaya G. Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association is significant in men but not in women. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1113-1123.
15. Kang H.J., Choe B.M., Kim S.H., Son S.R., Lee K.M., Kim B.G., et al. No association between functional polymorphisms in COMT and MTHFR and schizophrenia risk in Korean population. Epidemiology and Health 2010, 32:e2010011.
16. Kim S.G., Song J.Y., Joo E.J., Jeong S.H., Kim S.H., Lee K.Y., et al. No association of functional polymorphisms in methlylenetetrahydrofolate reductase and the risk and minor physical anomalies of schizophrenia in Korean population. Journal of Korean Medical Science 2011, 26:1356-1363.
17. Kunugi H., Fukuda R., Hattori M., Kato T., Tatsumi M., Sakai T., et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Molecular Psychiatry 1998, 3:435-437.
18. Philibert R., Gunter T., Hollenbeck N., Adams W.J., Bohle P., Packer H., et al. No association of the C677T methylenetetrahydrofolate reductase polymorphism with schizophrenia. Psychiatric Genetics 2006, 16:221-223.
19. Vilella E., Virgos C., Murphy M., Martorell L., Valero J., Simó J.M., et al. Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:1169-1174.
20. Virgos C., Martorell L., Simo J.M., Valero J., Figuera L., Joven J., et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. NeuroReport 1999, 10:2035-2038.
21. Yu L., Li T., Robertson Z., Dean J., Gu N.F., Feng G.Y., et al. No association between polymorphisms of methylenetetrahydrofolate reductase gene and schizophrenia in both Chinese and Scottish populations. Molecular Psychiatry 2004, 9:1063-1065.
22. Lewis S.J., Zammit S., Gunnell D., Smith G.D. A meta-analysis of the MTHFR C677T polymorphism and schizophrenia risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 135B:2-4.
23. Muntjewerff J.W., Kahn R.S., Blom H.J., Den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Molecular Psychiatry 2006, 11:143-149.
24. Peerbooms O.L., van Os J., Drukker M., Kenis G., Hoogveld L., MTHFR in Psychiatry Group, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability. Brain, Behavior, and Immunity 2011, 25:1530-1543.
25. Shi J., Gershon E.S., Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophrenia Research 2008, 104:96-107.
26. Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatric Genetics 2006, 16:105-115.
27. Yue W.H., Wang H.F., Sun L.D., Tang F.L., Liu Z.H., Zhang H.X., et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nature Genetics 2011, 43:1228-1231.
28. Owens S.F., Picchioni M.M., Rijsdijk F.V., Stahl D., Vassos E., Rodger A.K., et al. Genetic overlap between episodic memory deficits and schizophrenia: results from the Maudsley Twin Study. Psychological Medicine 2011, 41:521-532.
29. Sitskoorn M.M., Aleman A., Ebisch S.J., Appels M.C., Kahn R.S. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophrenia Research 2004, 71:285-295.
30. Roffman J.L., Gollub R.L., Calhoun V.D., Wassink T.H., Weiss A.P., Ho B.C., et al. MTHFR 677C→T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val→Met. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17573-17578.
31. Roffman J.L., Weiss A.P., Deckersbach T., Freudenreich O., Henderson D.C., Wong D.H., et al. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008, 147B:990-995.
32. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Human Molecular Genetics 2006, 15:3132-3145.
33. Mill J., Dempster E., Caspi A., Williams B., Moffitt T., Craig I. Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. American Journal of Medical Genetics Part B 2006, 141B:421-425.
34. Meyer-Lindenberg A., Weinberger D.R. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Reviews Neuroscience 2006, 7:818-827.
35. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
36. Fornito A., Yucel M., Patti J., Wood S.J., Pantelis C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophrenia Research 2009, 108:104-113.
37. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
38. Wang L., Metzak P.D., Honer W.G., Woodward T.S. Impaired efficiency of functional networks underlying episodic memory-for-context in schizophrenia. Journal of Neuroscience 2010, 30:13171-13179.
39. Cannon T.D., Thompson P.M., van Erp T.G., Toga A.W., Poutanen V.P., Huttunen M., et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:3228-3233.
40. Pietilainen O.P., Paunio T., Loukola A., Tuulio-Henriksson A., Kieseppä T., Thompson P., et al. Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009, 150B:683-692.
41. Thompson P.M., Cannon T.D., Narr K.L., van Erp T., Poutanen V.P., Huttunen M., et al. Genetic influences on brain structure. Nature Neuroscience 2001, 4:1253-1258.
42. Cuadra M.B., Cammoun L., Butz T., Cuisenaire O., Thiran J.P. Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Transactions on Medical Imaging 2005, 24:1548-1565.
43. Meisenzahl E.M., Koutsouleris N., Gaser C., Bottlender R., Schmitt G.J., McGuire P., et al. Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study. Schizophrenia Research 2008, 102:150-162.
44. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
45. Purcell S., Cherny S.S., Sham P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
46. Qiu L., Tian L., Pan C., Zhu R., Liu Q., Yan J., et al. Neuroanatomical circuitry associated with exploratory eye movement in schizophrenia: a voxel-based morphometric study. PLoS One 2011, 6:e25805.
47. Tian L., Meng C., Yan H., Zhao Q., Liu Q., Yan J., et al. Convergent evidence from multimodal imaging reveals amygdala abnormalities in schizophrenic patients and their first-degree relatives. PLoS One 2011, 6:e28794.
48. Hayasaka S., Phan K.L., Liberzon I., Worsley K.J., Nichols T.E. Nonstationary cluster-size inference with random field and permutation methods. Neuroimage 2004, 22:676-687.
49. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
50. Hokyo A., Kanazawa T., Uenishi H., Tsutsumi A., Kawashige S., Kikuyama H., et al. Habituation in prepulse inhibition is affected by a polymorphism on the NMDA receptor 2B subunit gene (GRIN2B). Psychiatric Genetics 2010, 20:191-198.
51. Lee Y.S., Han D.H., Jeon C.M., Lyoo I.K., Na C., Chae S.L., et al. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. NeuroReport 2006, 17:743-746.
52. Tan E.C., Chong S.A., Lim L.C., Chan A.O., Teo Y.Y., Tan C.H., et al. Genetic analysis of the thermolabile methylenetetrahydrofolate reductase variant in schizophrenia and mood disorders. Psychiatric Genetics 2004, 14:227-231.
53. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558.
54. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, " just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research 2008, 102:1-18.
55. Muntjewerff J.W., Ophoff R.A., Buizer-Voskamp J.E., Strengman E., Den Heijer M. Effects of seasons of birth and a common MTHFR gene variant on the risk of schizophrenia. European Neuropsychopharmacology 2011, 21:300-305. GROUP Consortium.
56. Roffman J.L., Weiss A.P., Deckersbach T., Freudenreich O., Henderson D.C., Purcell S., et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophrenia Research 2007, 92:181-188.
57. Picker J.D., Coyle J.T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia. Harvard Review of Psychiatry 2005, 13:197-205.
58. Singh S.M., McDonald P., Murphy B., O'Reilly R. Incidental neurodevelopmental episodes in the etiology of schizophrenia: an expanded model involving epigenetics and development. Clinical Genetics 2004, 65:435-440.
59. Singh S.M., Murphy B., O'Reilly R.L. Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia. Clinical Genetics 2003, 64:451-460.
60. Lee E.S., Chen H., Soliman K.F., Charlton C.G. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005, 26:361-371.
61. Hulshoff Pol H.E., Schnack H.G., Mandl R.C., van Haren N.E., Koning H., Collins D.L., et al. Focal gray matter density changes in schizophrenia. Archives of General Psychiatry 2001, 58:1118-1125.
62. Goldman-Rakic P.S. The cortical dopamine system: role in memory and cognition. Advances in Pharmacology 1998, 42:707-711.
63. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
64. Spaniol J., Davidson P.S., Kim A.S., Han H., Moscovitch M., Grady C.L. Event-related fMRI studies of episodic encoding and retrieval: Meta-analyses using activation likelihood estimation. Neuropsychologia 2009, 47:1765-1779.